Peripheral endomorphin-1 levels are suppressed in diabetic patients.

Diabetes Res Clin Pract

Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Affiliated with Shanghai Jiaotong University School of Medicine, China.

Published: February 2010


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Endomorphins are endogenous ligands selective for mu-opioid receptors, which have been reported to stimulate appetite and regulate glucose homeostasis. But there are no reports about changes in peripheral endomorphin-1 (EM-1) levels in diabetic patients. The aim of this study was to measure plasma EM-1 levels in fasting and postprandial conditions in diabetic patients.

Methods: After an overnight fast, 38 patients (mean age, 67+/-8 years; 17 males and 21 females) and 22 healthy volunteers (mean age, 64+/-9 years; 9 males and 13 females) received a standard breakfast meal with total energy content of 476.1kcal. Blood samples were drawn from each subject in heparinized tubes before breakfast and 2h postprandially. Plasma concentrations of EM-1 were measured by radioimmunoassay (RIA).

Results: Comparing with healthy volunteers, EM-1 levels were significantly lower in diabetic patients at both time-points (fasting: 48.38+/-14.13pg/ml vs. 72.71+/-19.62pg/ml, p<0.0001; postprandial: 39.80+/-12.28pg/ml vs. 62.93+/-21.95pg/ml, p=0.0001). When compared with fasting levels, the postprandial concentrations of EM-1 decreased in both diabetic patients, as well as healthy controls. The absolute value of decrease was not significantly different between the two groups.

Conclusions: Peripheral EM-1 levels were suppressed in diabetic patients and the levels decreased postprandially in both diabetic and healthy volunteers. This implies that EM-1 concentration has correlation with the change in glucose level. Thus, EM-1 could play a role in energy metabolism.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diabres.2009.11.017DOI Listing

Publication Analysis

Top Keywords

diabetic patients
12
em-1 levels
12
peripheral endomorphin-1
8
years males
8
males females
8
healthy volunteers
8
levels
4
endomorphin-1 levels
4
levels suppressed
4
diabetic
4

Similar Publications

Retinol binding protein 4 (RBP4), the circulating carrier of retinol, complexes with transthyretin (TTR) and is a potential biomarker of cardiometabolic disease. However, RBP4 quantitation relies on immunoassays and Western blots without retinol and TTR measurement. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous absolute quantitation of circulating RBP4 and TTR is critical to establishing their biomarker potential.

View Article and Find Full Text PDF

Introduction: Diabetes Mellitus is a chronic disease characterised by elevated plasma glucose (PG) levels. HbA1c has been widely utilized for diabetes diagnosis. However, certain conditions restrict its use.

View Article and Find Full Text PDF

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.

View Article and Find Full Text PDF

BackgroundCoronavirus Disease 2019 (COVID-19) has led to dramatic changes including social distancing, closure of schools, travel bans, and issues of stay-at-home orders. The health-care field has been transformed with elective procedures and on-site visits being deferred. Telemedicine has emerged as a novel mechanism to continue to provide care.

View Article and Find Full Text PDF

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a fairly new class of agents for diabetes that have demonstrated significant benefits in glycemic control and cardiovascular outcomes with outpatient use. The aim of this review is to provide an overview of the effect of SGLT2i use on glycemic control and clinical outcomes in the hospital setting.An electronic search of PubMed was conducted to analyze publications that assessed the inpatient use of SGLT2i and included patients with diabetes.

View Article and Find Full Text PDF